Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18106776 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL29434221 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL18590445 | 0.89 | ALDH1A1 (0.53) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL14338546 | 0.86 | ALDH1A1 (0.65) | ALDH1A1CYP2C19LMNACNR1MEN1 | |
| SCHEMBL221514 | 0.85 | CNR1 (0.49) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL221513 | 0.85 | CNR1 (0.49) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL18106777 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL18106707 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL18106496 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL29434418 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3305763-B1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | KYORIN SEIYAKU KK (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180290974-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| EP-3305763-A1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9822069-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9822069-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| EP-3075726-B1 | UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FORMYL PEPTIDE RECEPTOR LIKE 1 (FPRL-1) AGONISTS | KYORIN SEIYAKU KK (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3075726-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-3075726-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079692-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | 杏林製薬株式会社 | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-20180290974-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | ALDH1A1 2202/4885CYP2C19 1641/4885LMNA 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.